A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients
Status:
Completed
Trial end date:
2020-11-11
Target enrollment:
Participant gender:
Summary
This trial assesses the safety of TEV-48125 when subcutaneously self-administered in Japanese
migraine patients using an autoinjector (AI) at home. Each subject will subcutaneously
self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.
The first dose will be self-administered at the trial site under the supervision of the
investigator and the second dose will be self-administered at home.